Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,400 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $18.21, for a total transaction of $152,964.00. Following the completion of the sale, the chief executive officer now owns 555,044 shares in the company, valued at $10,107,351.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) remained flat at $19.45 on Thursday. 196,158 shares of the company were exchanged. Atara Biotherapeutics Inc. has a 52 week low of $12.45 and a 52 week high of $40.80. The stock’s market cap is $561.33 million. The company has a 50 day moving average price of $16.69 and a 200 day moving average price of $19.65.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. On average, equities research analysts forecast that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

A number of analysts recently commented on ATRA shares. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 16th. Citigroup Inc. boosted their price target on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Jefferies Group initiated coverage on shares of Atara Biotherapeutics in a report on Monday, October 24th. They set a “buy” rating and a $23.00 price target on the stock. Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their price target for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Canaccord Genuity set a $47.00 price target on shares of Atara Biotherapeutics and gave the company a “buy” rating in a report on Sunday, November 6th. Three research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $25.86.

A number of large investors have recently modified their holdings of ATRA. BlackRock Inc. raised its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares in the last quarter. BlackRock Investment Management LLC raised its position in shares of Atara Biotherapeutics by 66.3% in the second quarter. BlackRock Investment Management LLC now owns 94,203 shares of the company’s stock valued at $2,121,000 after buying an additional 37,557 shares during the period. BlackRock Advisors LLC raised its position in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock valued at $229,000 after buying an additional 2,361 shares during the period. Vanguard Group Inc. raised its position in shares of Atara Biotherapeutics by 20.3% in the second quarter. Vanguard Group Inc. now owns 679,690 shares of the company’s stock valued at $15,300,000 after buying an additional 114,734 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Atara Biotherapeutics by 38.0% in the second quarter. Nationwide Fund Advisors now owns 15,110 shares of the company’s stock valued at $340,000 after buying an additional 4,159 shares during the period. 74.45% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics Inc. (ATRA) CEO Isaac E. Ciechanover Sells 8,400 Shares” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/24/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-8400-shares.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.